仅接受最佳支持治疗的表皮生长因子受体突变型非小细胞肺癌患者基因突变的预后意义。
Prognostic Significance of Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
机构信息
Department of Respiratory Medicine, Hiroshima University Hospital, Hiroshima, Japan;
Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.
出版信息
Anticancer Res. 2021 May;41(5):2661-2667. doi: 10.21873/anticanres.15047.
BACKGROUND/AIM: The significance of epidermal growth factor receptor (EGFR) mutation in untreated patients with non-small cell lung cancer (NSCLC) remains uncertain. We aimed to determine the significance of EGFR mutation in patients who received best supportive care (BSC) alone, and compare the outcomes of only EGFR- tyrosine kinase inhibitors (TKI)-treated vs. BSC patients.
PATIENTS AND METHODS
Between April 1991-August 2018, 1,197 patients diagnosed with unresectable NSCLC at our institutions were enrolled in the study.
RESULTS
Among 226 patients who underwent EGFR mutation analysis and received BSC alone, 35 and 191 did and did not harbor the mutation, and the median survival times (MST) did not differ significantly between these groups. A comparison of only EGFR-TKI-treated and BSC patients with EGFR mutation revealed that the former had a three times longer MST than the latter.
CONCLUSION
Our results may help explain the benefit of EGFR-TKI for patients who would be directed towards BSC.
背景/目的：表皮生长因子受体（EGFR）突变在未经治疗的非小细胞肺癌（NSCLC）患者中的意义仍不确定。我们旨在确定仅接受最佳支持治疗（BSC）的患者中 EGFR 突变的意义，并比较仅接受 EGFR-酪氨酸激酶抑制剂（TKI）治疗与 BSC 患者的结局。
患者和方法
1991 年 4 月至 2018 年 8 月，在我们的机构中诊断为不可切除 NSCLC 的 1197 名患者被纳入该研究。
结果
在 226 名接受 EGFR 突变分析且仅接受 BSC 的患者中，35 名和 191 名患者携带和不携带突变，两组之间的中位生存期（MST）无显著差异。仅接受 EGFR-TKI 治疗和 BSC 且有 EGFR 突变的患者相比，前者的 MST 比后者长三倍。
结论
我们的结果可能有助于解释 EGFR-TKI 对将接受 BSC 治疗的患者的益处。
Zotero 插件